MOLECULAR INFORMATION
Molecular information
- Type
- Angiotensin-IV analogue · claimed HGF/c-Met activator · oral bioavailability
Dihexa is a research-grade hexapeptide derivative of angiotensin IV, marketed grey-market for nootropic claims.
Claims vs evidence
- Synaptogenesis / memory consolidation — rodent models only
- Alzheimer’s-disease research interest — preclinical
- Nootropic effects in healthy humans — extrapolated, no RCT
Why we grade it D
Single-research-group preclinical evidence with no human translation. Grey-market vendors extrapolate claims well beyond the data.
Frequently asked questions
- What is Dihexa?
- An angiotensin-IV-derived hexapeptide analogue. Claimed to act as a hepatocyte growth factor (HGF) / c-Met agonist, driving synaptogenesis and memory consolidation in rodent models.
- Is Dihexa authorised?
- No — no major regulator has authorised it. Sold grey-market for nootropic / Alzheimer's-research claims.
- Why grade D?
- Mechanism work comes almost entirely from one research group (Harding et al., Washington State University). No independent human RCT exists. The compound is sold with extrapolated cognitive-enhancement claims that the data does not support.